Clinical trials: Addiction, Substance
Substance Dependence
A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence
Purpose: This is an outpatient, randomized, double-blinded, placebo-controlled study in which either varenicline (twice daily) or placebo will be administered over a 12 week study period to examine genetic influences on treatment…
- Trial name
- NCT01011907
- Testing
- varenicline
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- University of California, San Francisco
Opioid Addiction, Opioid Abuse, Continuous Use
Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction
Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth.
- Conditions
- Opioid Addiction, Opioid Abuse, Continuous Use, Opioid Use, Opioid-Related Disorders
- Trial name
- NCT03394911
- Testing
- 250mg healthy adult male facial skin surface lipid liquid pheromone
- Volunteers
- 500 people
- Sponsor
- Bubba Nicholson
Substance-related Disorders
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
Tobacco, alcohol and opioid use disorders threaten the health of HIV-infected patients. What if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction…
- Trial name
- WHAT-IF? (NCT02907944)
- Testing
- Implementation Facilitation
- Where
- 4 sites in United States
- Volunteers
- 3,838 people
- Sponsor
- Yale University
Tobacco Use Disorder, Smoking Cessation
Deep rTMS and Varenicline for Smoking Cessation
The purpose of this study is to investigate the effect of deep repetitive transcranial magnetic stimulation (rTMS) using the insula H-coil on smoking outcomes in smokers receiving varenicline.
- Trial name
- NCT04083144
- Testing
- Deep Repetitive Transcranial Magnetic Stimulation (Active), Varenicline
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre for Addiction and Mental Health
Cocaine Dependence
Therapeutic Cocaine Vaccine: Human Laboratory Study
Clinical data demonstrate that a cocaine vaccine (TA-CD: Celtic Pharmaceutical) produces selective anti-cocaine antibodies, yet the impact of these antibodies on cocaine's direct effects is unknown.
- Trial name
- NCT00965263
- Testing
- Cocaine vaccine (TA-CD)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Marijuana Dependence
Effect of Oxytocin on Craving and Therapy Response
The purpose of this study is to examine the impact of a medication called oxytocin on marijuana use and therapy response in people who frequently use marijuana.
- Trial name
- NCT01827332
- Testing
- Oxytocin, Saline
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Benzodiazepine Dependence, Benzodiazepine Abuse
Prevention of Benzodiazepine Misuse in Primary Care
Benzodiazepines and benzodiazepine-like hypnotics (z-drugs) are prevalent and addictive narcotics. Guidelines recommend restricted prescription of these drugs for anxiety and insomnia.
- Conditions
- Benzodiazepine Dependence, Benzodiazepine Abuse, Substance Use Disorders
- Trial name
- NCT04533230
- Testing
- Educational intervention with prescription feedback, Information on treatment guidelines
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Nicotine Dependence
Studying Nicotine Addiction With Transcranial Magnetic Stimulation
Background: Nicotine addiction often makes it difficult to stop smoking. Researchers want to understand the areas of the brain that are important in nicotine addiction.
- Trial name
- NCT01702948
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD).
- Trial name
- NCT07227948
- Testing
- Semaglutide, cognitive behavioral therapy (CBT).
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV, Medication Adherence
Intervention Targeting Substance Using Older Adults With HIV
The proposed study uses a randomized controlled experimental design to evaluate the efficacy of a brief intervention using spiritual self schema (3S+) counseling to simultaneously target HIV health outcomes, and substance use…
- Conditions
- HIV, Medication Adherence, Substance Dependence
- Trial name
- NCT01305629
- Testing
- Spiritual Self-Schema Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Hunter College of City University of New York
Substance Dependence
GSK618334 Repeat Dose Study
The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
- Trial name
- NCT01036061
- Testing
- GSK618334 Low Dose, GSK618334 PET subjects, GSK618334 Medium Dose
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Marijuana Abuse, Psychotic Disorders
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
The purpose of the trial is to investigate the effect of specialized treatment of cannabis abuse among young people with psychosis. The specialized treatment consists of manualized individual treatment and group therapy.
- Conditions
- Marijuana Abuse, Psychotic Disorders, Schizophrenia
- Trial name
- CapOpus (NCT00484302)
- Testing
- Cognitive behavioral therapy with motivational interviewing, Non-manualized standard treatment
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Bispebjerg Hospital
Mental Disorders, Drug Addiction
Treatment of Hepatitis C in Psychiatric Patients
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of Interferon-alpha in patients with chronic hepatitis C.
- Trial name
- NCT00751426
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Charite University, Berlin, Germany
PTSD, Depression
Participatory System Dynamics vs Usual Quality Improvement: Staff Use of Simulation as an Effective, Scalable and Affordable Way to Improve Timely Mental Health Care?
Evidence-based VA care is best for meeting Veterans' mental health needs, such as depression, PTSD and opioid use disorder, to prevent suicide or overdose. But some key evidence-based practices only reach 3-28% of patients.
- Conditions
- PTSD, Depression, Opioid Use Disorder
- Trial name
- NCT04208217
- Testing
- Modeling to Learn (MTL), Usual quality improvement (QI)
- Where
- United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alcohol Use Disorder, Cannabis Use Disorder
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
This 2-arm study will recruit participants with 1) alcohol use disorder and 2) cannabis use disorder for a 12-week cognitive behavioral therapy, following a thorough baseline assessments on executive function, incentive salience…
- Trial name
- NCT05855668
- Testing
- CBT
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- Centre for Addiction and Mental Health
Implementation Science, Chronic Disease Self-management
Adapting and Implementing a Chronic Disease Self-Management Program for Primary Care Patients With Opioid Use Disorder and Serious Mental Illness
The purpose of this study is to evaluate a self-management education program designed to help people with opioid use disorder (OUD), serious mental illness (SMI), and other chronic health conditions better manage their health.
- Conditions
- Implementation Science, Chronic Disease Self-management, Mental Illness, Addiction
- Trial name
- NCT07865078
- Testing
- The Chronic Disease Self-Management Program (CDSMP), Treatment as Usual plus self-management information
- Volunteers
- 40 people
- Sponsor
- University of Utah
Opioid Use Disorder
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention.
- Trial name
- SARA RCT (NCT06732596)
- Testing
- Embodied conversational agent (ECA), Technical support, Additional ECA messages
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Medical Center
Intensive Care Unit Syndrome, Drug Abuse
Addiction in Intensive Cardiac Care Units
Background: Illicit drug use is a growing issue in Europe and leading cause of acute cardiac events in patients admitted to intensive cardiac care units.
- Conditions
- Intensive Care Unit Syndrome, Drug Abuse, Substance-Related Disorders, Cardiovascular Events
- Trial name
- ADDICT-CCU (NCT05063097)
- Testing
- urine test, Fagerström questionnaire, Exhaled carbon monoxide (CO) measurement
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Smoking, Tobacco Smoking
Pilot Study of Contingency Management for Smoking Cessation
The purpose of this study is to see whether contingency management (CM) can be successfully added as an adjunct treatment to standard stop smoking services in outpatients undergoing treatment for opiate addiction.
- Conditions
- Smoking, Tobacco Smoking, Smoking, Tobacco, Smoking Cessation
- Trial name
- NCT03015597
- Testing
- Contingency Management
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- King's College London
Opioid-use Disorder
Treatment for Opiate Addiction: Prognostic fActors of Responsiveness to Maintenance Treatment
A global and integrative treatment of opioid-use disorders (OUD) with opiate maintenance therapy (OMT) and psychosocial interventions is recommended by all current guidelines.
- Trial name
- TOPAZE (NCT03729388)
- Testing
- Prognosis factor associated with good outcome.
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital